SUNDAY, MARCH 17
Arrival and Registration

MONDAY, MARCH 18
Welcome and Keynote Address
James P. Allison, University of Texas MD Anderson Cancer Center, USA
Immune Checkpoint Blockade in Cancer Therapy: New Insights into Therapeutic Mechanisms of anti-CTLA4 and anti-PD-1

Clinical Trials to Identify Mechanisms of Response and Resistance
Andrea Cercek, Memorial Sloan Kettering Cancer Center, USA
Single Agent PD-1 Blockade as Curative-Intent Treatment in Mismatch Repair Deficient Locally Advanced Rectal Cancer
Antoni Ribas, University of California, Los Angeles, USA
Role of IFN-gamma in Response and Resistance to Cancer Immunotherapies
Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
Neoadjuvant and Tissue-based Trials for Evaluating Mechanisms of Response and Resistance
Georgina V. Long, Melanoma Institute Australia, The University of Sydney, Australia
Neo-adjuvant Therapy: Where We Have Come from and Where to Next

Panel Discussion on Failed Trials
*Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
*Antoni Ribas, University of California, Los Angeles, USA
Georgina V. Long, Melanoma Institute Australia, The University of Sydney, Australia

Regulation of Immune Responses by Myeloid Cells, Dendritic Cells and Tertiary Lymphoid Structures
Miriam Merad, Mount Sinai School of Medicine, USA
Molecular and Spatial Correlates of Response to PD-1 Blockade in Human Tumors
Haydn Kissick, Emory University, USA
CD8 T Cell Activation [by Dendritic Cells] in Cancer is Comprised of Two Distinct Phases
Stefani Spranger, Massachusetts Institute of Technology, USA
Not All Anti-Tumor T Cell Responses are Created Equal: Why Dendritic Cells Matter
Gabriel A. Rabinovich, Instituto de Biologia y Medicina Experimental, Argentina
Galectins: Emerging Glyco-Checkpoints in the Tumor Microenvironment

Poster Session 1

TUESDAY, MARCH 19
Novel Insights into T Cell Biology
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, USA
Talk Title to be Announced
Pablo Umaña, Roche Innovation Center Zürich, Switzerland
PD-1 + IL-2 to Drive Differentiation of Effector T Cells in Tumor
Judith Agudo, Dana-Farber Cancer Institute, USA
Uncovering Hidden Drivers of Immune Evasion: Stemness and Cell Cycle
Speaker to be Announced
Short Talks Chosen from Abstracts

Career Roundtable
Understanding Spatial Temporal Interactions Guiding Response and Resistance in the Tumor and Lymph Nodes
Ronald N. Germain, NIAID, National Institutes of Health, USA
Gaining Insight into Tumor Immunity by Combining New Highly Multiplex 2D and 3D Imaging with Analytical Tools
Garry P. Nolan, Stanford University, USA
Immune Pathology from the Subcellular Scale on Up
Brian D. Brown, Mount Sinai School of Medicine, USA
Spatial CRISPR
Short Talks Chosen from Abstracts

Poster Session 2

WEDNESDAY, MARCH 20
Engineering T Cells to Overcome Immune Resistance
Yvonne Y. Chen, University of California, Los Angeles, USA
Engineering Next-Generation CAR-T Cells for Cancer Immunotherapy
Avery D. Posey, University of Pennsylvania, USA
Chimeric Antigen Receptor T-Cells and Carbohydrate-Based Cancer Targets
Justin Eyquem, University of California, San Francisco, USA
Synthetic Immunology and Genome Editing Tools to Advance T Cell Therapies
Short Talks Chosen from Abstracts

Tumor Antigens and Cancer Vaccines
Catherine J. Wu, Dana-Farber Cancer Institute, USA
Building Personalized Cancer Vaccines
Alena Gros, Vall d’Hebron Institute of Oncology, Spain
Neoantigen Targeting with Tumor Infiltrating Lymphocytes
Short Talks Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

THURSDAY, MARCH 21